Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04571645 · ClinicalTrials.gov registry record · Phase 3
Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia
A Phase 3 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 9
- Enrollment target
NCT04571645 is a Phase 3 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT04571645, a Phase 3 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 9 participants
- Enrollment target
Study Summary
Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.
Interventions
- OTHER Control
- DRUG Dociparstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2021-04-30 |
| Est. Completion | 2022-05-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04571645
The ClinicalTrials.gov registry entry for NCT04571645 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT04571645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04571645 about?
NCT04571645 is a clinical study titled "Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia". Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated acute myeloid leukemia (AML) with adverse or intermediate genetic risk.
What is the current status of trial NCT04571645?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 9 participants. The study started on 2021-04-30. Estimated completion is 2022-05-16.
What interventions are being tested in trial NCT04571645?
The interventions under investigation include: Control (OTHER), Dociparstat (DRUG).
Who is sponsoring clinical trial NCT04571645?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.